Systemic Antifungal Agents: An Update of Established and New Therapies

Advances in Dermatology

Volumn 22, Issue , 2006, Pages 101-124

  Loo, Daniel S ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; TRIAZOLE DERIVATIVE;

CHEMISTRY; HUMAN; ONYCHOMYCOSIS; REVIEW; TINEA CAPITIS;

ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; HUMANS; ONYCHOMYCOSIS; TINEA CAPITIS; TRIAZOLES;

EID: 33845670074     PISSN: 08820880     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yadr.2006.07.001     Document Type: Review

References (60)

1. Gupta A.K., Ryder J.E., and Johnson A.M. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol 150 (2004) 537-544
2. Cribier B.J., and Paul C. Long-term efficacy of antifungals in toenail onychomycosis: a critical review. Br J Dermatol 145 (2001) 446-452
3. Török I., Simon G., Dobozy A., et al. Long-term post-treatment follow-up of onychomycosis treated with terbinafine: a multicentre trial. Mycoses 41 (1998) 63-65
4. Bräutigam M., Weidinger G., and Nolting S. Successful treatment of toenail mycosis with terbinafine and itraconazole gives long term benefits. BMJ 317 (1998) 1084
5. Tosti A., Piraccini B.M., Stinchi C., et al. Relapses of onychomycosis after successful treatment with systemic antifungals: a three-year follow-up. Dermatology 197 (1998) 162-166
6. Scher R.K., Breneman D., Rich P., et al. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol 38 6 Pt 2 (1998) S77-S86
7. Sigurgeirsson B., Olafsson J.H., Steinsson J.B., et al. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol 138 (2002) 353-357
8. Schatz F., Brautigam M., Dobrowolski E., et al. Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin Exp Dermatol 20 (1995) 377-383
9. Alpsoy E., Yilmaz E., and Basaran E. Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: a new approach. J Dermatol 23 (1996) 259-262
10. Tosti A., Piraccini B.M., Stinchi C., et al. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol 34 (1996) 595-600
11. Gupta A.K., Lynde C.W., and Konnikov N. Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. J Am Acad Dermatol (2001) 44485-91
12. Warshaw E.M., Fett D.D., Bloomfield H.E., et al. Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled trial. J Am Acad Dermatol (2005) 53578-84
13. Gupta A.K., Jain H.C., Lynde C.W., et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter canadian survey of 15,000 patients. J Am Acad Dermatol 43 2 Pt 1 (2000) 244-248
14. Nsanze H., Lestringant G.G., Mustafa N., et al. Aetiology of onychomycosis in Al Ain, United Arab Emirates. Mycoses 38 (1995) 421-424
15. Gupta A.K., De Doncker P., and Haneke E. Itraconazole pulse therapy for the treatment of Candida onychomycosis. J Eur Acad Dermatol Venereol 15 (2001) 112-115
16. Lebwohl M.G., Daniel C.R., Leyden J., et al. Efficacy and safety of terbinafine for nondermatophyte and mixed nondermatophyte and dermatophyte toenail onychomycosis. Int J Dermatol 40 (2001) 358-360
17. Segal R., Kritzman A., Cividalli L., et al. Treatment of Candida nail infection with terbinafine. J Am Acad Dermatol 35 (1996) 958-961
18. Zaidi Z., Jafri N., Khan K., et al. Open label trial of the efficacy and tolerability of Lamisil (Terbinafine) 500 mg once daily in the treatment of onychomycosis due to candida. J Pak Med Assoc 46 (1996) 258-260
19. Scher R.K., and Baran R. Onychomycosis in clinical practice: factors contributing to recurrence. Br J Dermatol 149 Suppl 65 (2003) 5-9
20. Friedlander S.F. The evolving role of itraconazole, fluconazole and terbinafine in the treatment of tinea capitis. Pediatr Infect Dis J 18 (1999) 205-210
21. Elewski B.E. Tinea capitis: a current perspective. J Am Acad Dermatol 42 1 Pt 1 (2000) 1-20 [quiz 21-4]
22. Physician's desk reference. 59th ed. (2005), Thomson PDR, Montvale (NJ)
23. Lipozencic J., Skerlev M., Orofino-Costa R., et al. A randomized, double-blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to Microsporum species. Br J Dermatol 146 (2002) 816-823
24. Gupta A.K., Adam P., Dlova N., et al. Therapeutic options for the treatment of tinea capitis caused by Trichophyton species: griseofulvin versus the new oral antifungal agents, terbinafine, itraconazole, and fluconazole. Pediatr Dermatol 18 (2001) 433-438
25. Foster K.W., Friedlander S.F., Panzer H., et al. A randomized controlled trial assessing the efficacy of fluconazole in the treatment of pediatric tinea capitis. J Am Acad Dermatol 53 (2005) 798-809
26. Friedlander S.F., Aly R., Krafchik B., et al. Terbinafine in the treatment of Trichophyton tinea capitis: a randomized, double-blind, parallel-group, duration-finding study. Pediatrics 109 (2002) 602-607
27. Devliotou-Panagiotidou D., and Koussidou-Eremondi T.H. Efficacy and tolerability of 8 weeks' treatment with terbinafine in children with tinea capitis caused by Microsporum canis: a comparison of three doses. J Eur Acad Dermatol Venereol 18 (2004) 155-159
28. Ungpakorn R., Ayutyanont T., Reangchainam S., et al. Treatment of Microsporum spp. tinea capitis with pulsed oral terbinafine. Clin Exp Dermatol 29 (2004) 300-303
29. Ginter-Hanselmayer G., Smolle J., and Gupta A. Itraconazole in the treatment of tinea capitis caused by Microsporum canis: experience in a large cohort. Pediatr Dermatol 21 (2004) 499-502
30. Solomon B.A., Collins R., Sharma R., et al. Fluconazole for the treatment of tinea capitis in children. J Am Acad Dermatol 37 2 Pt 1 (1997) 274-275
31. Gupta A.K., Adam P., Hofstader S.L., et al. Intermittent short duration therapy with fluconazole is effective for tinea capitis. Br J Dermatol 141 (1999) 304-306
32. Montero-Gei F. Fluconazole in the treatment of tinea capitis. Int J Dermatol 37 11 (1998) 870-871
33. Gupta A.K., Dlova N., Taborda P., et al. Once weekly fluconazole is effective in the treatment of tinea capitis: a prospective, multicentre study. Br J Dermatol 142 5 (2000) 965-968
34. Gan V.N., Petruska M., and Ginsburg C.M. Epidemiology and treatment of tinea capitis: ketoconazole vs. griseofulvin. Pediatr Infect Dis J 6 (1987) 46-49
35. Alvi K.H., Iqbal N., and Khan K.A. A randomized double-blind trial of the efficacy and tolerability of terbinafine once daily compared to griseofulvin once daily in the treatment of tinea capitis. In: Shuster S., and Jafary M.H. (Eds). Terbinafine in treatment of superficial fungal infections. International congress series (1993), Royal Society of Medicine Services, London 35-40
36. Lopez-Gomez S., Del Palacio A., Van Cutsem J., et al. Itraconazole versus griseofulvin in the treatment of tinea capitis: a double-blind randomized study in children. Int J Dermatol 33 (1994) 743-747
37. Donnelly J.P., and De Pauw B.E. Voriconazole-a new therapeutic agent with an extended spectrum of antifungal activity. Clin Microbiol Infect 10 Suppl 1 (2004) 107-117
38. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347 (2002) 408-415
39. Ally R., Schurmann D., Kreisel W., et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 33 (2001) 1447-1454
40. Gupta A.K., Kohli Y., and Batra R. In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species. Med Mycol 43 (2005) 179-185
41. Kontoyiannis D.P., Lionakis M.S., Lewis R.E., et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 191 (2005) 1350-1360
42. Cuenca-Estrella M., Gomez-Lopez A., Mellado E., et al. In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi. Antimicrob Agents Chemother 49 (2005) 5136-5138
43. Cuenca-Estrella M., Gomez-Lopez A., Mellado E., et al. In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates. Antimicrob Agents Chemother 48 (2004) 3107-3111
44. Gupta A.K., Leonardi C., Stoltz R.R., et al. A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J Eur Acad Dermatol Venereol 19 (2005) 437-443
45. Guimera-Martin-Neda F., Garcia-Bustinduy M., Noda-Cabrera A., et al. Cutaneous infection by Fusarium: successful treatment with oral voriconazole. Br J Dermatol 150 (2004) 777-778
46. Lacroix C., de Kerviler E., Morel P., et al. Madurella mycetomatis mycetoma treated successfully with oral voriconazole. Br J Dermatol 152 (2005) 1067-1068
47. Bosma F., Voss A., van Hamersvelt H.W., et al. Two cases of subcutaneous Scedosporium apiospermum infection treated with voriconazole. Clin Microbiol Infect 9 (2003) 750-753
48. Schaenman J.M., Digiulio D.B., Mirels L.F., et al. Scedosporium apiospermum soft tissue infection successfully treated with voriconazole: potential pitfalls in the transition from intravenous to oral therapy. J Clin Microbiol 43 (2005) 973-977
49. Negroni R., Helou S.H., Petri N., et al. Case study: posaconazole treatment of disseminated phaeohyphomycosis due to Exophiala spinifera. Clin Infect Dis 38 (2004) e15-e20
50. Mora-Duarte J., Betts R., Rotstein C., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347 (2002) 2020-2029
51. Villanueva A., Gotuzzo E., Arathoon E.G., et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 113 (2002) 294-299
52. Kartsonis N., DiNubile M.J., Bartizal K., et al. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J Acquir Immune Defic Syndr 31 (2002) 183-187
53. Walsh T.J., Teppler H., Donowitz G.R., et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351 (2004) 1391-1402
54. Maertens J., Raad I., Petrikkos G., et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39 (2004) 1563-1571
55. Kohno S., Masaoka T., Yamaguchi H., et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 36 (2004) 372-379
56. de Wet N., Llanos-Cuentas A., Suleiman J., et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 39 (2004) 842-849
57. Pettengell K., Mynhardt J., Kluyts T., et al. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther 20 (2004) 475-481
58. van Burik J.A., Ratanatharathorn V., Stepan D.E., et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39 (2004) 1407-1416
59. Krause D.S., Reinhardt J., Vazquez J.A., et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 48 (2004) 2021-2024
60. Krause D.S., Simjee A.E., van Rensburg C., et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 39 (2004) 770-775